Research Article
Clinical and Functional Characteristics of a Novel KLF11 Cys354Phe Variant Involved in Maturity-Onset Diabetes of the Young
Table 2
Clinical characteristics of the study family.
| | Proband | Maternal grandfather | Mother‡ | Father‡ |
| | Birth weight (kg) | 3.15 | No data | No data | No data | | At diagnosis | | Age (yr) | 23 | 66 | — | — | | Height (cm) | 168.5 | 172 | — | — | | Body weight (kg) | 54 | 65 | — | — | | BMI (kg/m2) | 19.02 | 21.97 | — | — | | DKA† | No | No | — | — | | Blood glucose (mmol/L) | 13.9 | No data | — | — | | HbA1c (NGSP, %) | 11.5 | No data | — | — | | At the latest examination | | Age (yr) | 24 | 70 | 50 | 50 | | Height (cm) | 168.5 | 172 | 163 | 173 | | Body weight (kg) | 50 | 55 | 50 | 65 | | BMI (kg/m2) | 17.61 | 18.59 | 18.82 | 21.72 | | HbA1c (NGSP, %) | 5.9 | 6.0 | 5.1 | 4.6 | | Fasting serum C-peptide (ng/mL) | 0.31 | 0.72 | 0.50 | 0.73 | | Fasting serum insulin (μIU/mL) | 8.99 | 4.74 | 4.09 | 2.65 | | Treatment plan | Insulin glargine injection (10 units at bedtime), saxagliptin (2.5 mg once/day), voglibose (0.2 mg three times/day) | Metformin hydrochloride 1000 mg/day; gliclazide 160 mg/day | — | — |
|
|
†DKA: diabetic ketoacidosis. ‡This individual had no diabetes.
|
